ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0444

Chronological Order of Decrease of Synovitis, Osteitis and Tenosynovitis in Early Arthritis Patients Receiving First DMARD-treatment

Xanthe Matthijssen1, Ellis Niemantsverdriet1, Saskia le Cessie1 and Annette van der Helm - van Mil2, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

Meeting: ACR Convergence 2020

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), Magnetic resonance imaging (MRI), rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Imaging of Rheumatic Diseases (0444–0448)

Session Type: Abstract Session

Session Time: 10:00AM-10:50AM

Background/Purpose: Advanced imaging modalities have shown that not only joints but also bones and tendon sheaths can be inflamed at diagnosis of rheumatoid arthritis. We aimed to better understand the time order in which the inflamed tissues respond to DMARD-treatment and whether this differs between ACPA-subgroups.

Methods: 216 consecutive patients presenting with undifferentiated or rheumatoid arthritis, who received DMARD-treatment, were studied. 1.5T contrast-enhanced hand and foot MRIs were performed before treatment and after 4, 12 and 24-months. Cross-lagged models evaluated the influence of two time-patterns: a simultaneous pattern (“change in one inflammatory feature associated with change in another feature”) and a subsequent pattern (“change in one inflammatory feature preceded change in another feature”). ACPA-stratification was performed.

Results: All pairs of inflammatory features decreased simultaneously in all time-intervals (0–4/4–12/12–24m; p< 0.05). Moreover, time orders were identified: synovitis decrease preceded tenosynovitis decrease (0-4m- >4-12m; p=0.02 & 4-12m- >12-24m; p=0.03). Similar results were obtained in both ACPA-subgroups. Additionally, in ACPA-positive but not ACPA-negative patients, synovitis decrease preceded osteitis decrease (4-12m- >12-24m; p=0.002).

Conclusion: This study increased the understanding of the response to treatment on tissue level. Additional to simultaneous decrease of inflammation, synovitis decrease preceded tenosynovitis decrease. Differences in time order of inflammation decrease between ACPA-subgroups suggest differences in underlying inflammatory pathways.


Disclosure: X. Matthijssen, None; E. Niemantsverdriet, None; S. le Cessie, None; A. van der Helm - van Mil, None.

To cite this abstract in AMA style:

Matthijssen X, Niemantsverdriet E, le Cessie S, van der Helm - van Mil A. Chronological Order of Decrease of Synovitis, Osteitis and Tenosynovitis in Early Arthritis Patients Receiving First DMARD-treatment [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/chronological-order-of-decrease-of-synovitis-osteitis-and-tenosynovitis-in-early-arthritis-patients-receiving-first-dmard-treatment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chronological-order-of-decrease-of-synovitis-osteitis-and-tenosynovitis-in-early-arthritis-patients-receiving-first-dmard-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology